Methyl 14-cyclohexyl-5-[2-(dimethylamino)ethyl]-6-oxo-5,6,7,8-tetrahydroindolo[1,2-e][1,5]benzodiazocine-11-carboxylate | 885479-45-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Methyl 14-cyclohexyl-5-[2-(dimethylamino)ethyl]-6-oxo-5,6,7,8-tetrahydroindolo[1,2-e][1,5]benzodiazocine-11-carboxylate
• 英文别名: methyl 19-cyclohexyl-8-[2-(dimethylamino)ethyl]-9-oxo-8,12-diazatetracyclo[10.7.0.02,7.013,18]nonadeca-1(19),2,4,6,13(18),14,16-heptaene-15-carboxylate
• CAS: 885479-45-8
• 化学式: C₂₉H₃₅N₃O₃
• 分子量: 473.615
• InChiKey: NOIHHBRDBGEFEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  54.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Methyl 14-cyclohexyl-5-[2-(dimethylamino)ethyl]-6-oxo-5,6,7,8-tetrahydroindolo[1,2-e][1,5]benzodiazocine-11-carboxylate 在 dimethyl sulfide borane 作用下， 以 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymerase

  摘要：

  We report the evolutionary path from an open-chain series to conformationally constrained tetracyclic indole inhibitors of HCV NS5B-polymerase, where the C2 aromatic is tethered to the indole nitrogen. SAR studies led to the discovery of zwitterionic compounds endowed with good intrinsic enzyme affinity and cell-based potency, as well as superior DMPK profiles to their acyclic counterparts, and ultimately to the identification of a pre-clinical candidate with an excellent predicted human pharmacokinetic profile. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.068
• 作为产物：
  描述：

  Methyl 14-cyclohexyl-6-oxo-5,6,7,8-tetrahydroindolo[1,2-e][1,5]benzodiazocine-11-carboxylate 、 alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 Methyl 14-cyclohexyl-5-[2-(dimethylamino)ethyl]-6-oxo-5,6,7,8-tetrahydroindolo[1,2-e][1,5]benzodiazocine-11-carboxylate
  参考文献：
  名称：

  Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymerase

  摘要：

  We report the evolutionary path from an open-chain series to conformationally constrained tetracyclic indole inhibitors of HCV NS5B-polymerase, where the C2 aromatic is tethered to the indole nitrogen. SAR studies led to the discovery of zwitterionic compounds endowed with good intrinsic enzyme affinity and cell-based potency, as well as superior DMPK profiles to their acyclic counterparts, and ultimately to the identification of a pre-clinical candidate with an excellent predicted human pharmacokinetic profile. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.068

文献信息

• Tetracyclic Indole Derivatives as Antiviral Agents
  申请人：Ercolani Caterina

  公开号：US20080261938A1

  公开（公告）日：2008-10-23

  The present invention relates to tetracyclic indole compounds of formula (I); wherein R 1 , R 2 , R 14 , R 15 , A, Ar, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.

  本发明涉及式(I)的四环吲哚化合物；其中R1、R2、R14、R15、A、Ar、Y和Z在此定义，以及其药学上可接受的盐、包括它们的制药组合物，以及它们用于治疗或预防丙型肝炎病毒感染的用途。
• Tetracyclic indole derivatives as antiviral agents
  申请人：Istituto di Richerche di Biologia Molecolare P Angeletti SpA

  公开号：US07662809B2

  公开（公告）日：2010-02-16

  The present invention relates to tetracyclic indole compounds of formula (I); wherein R1, R2, R14, R15, A, Ar, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.

  本发明涉及式(I)的四环吲哚化合物；其中R1、R2、R14、R15、A、Ar、Y和Z在此定义，并且其药学上可接受的盐，包括它们的制药组合物，以及它们用于治疗或预防丙型肝炎病毒感染的用途。
• TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS
  申请人：Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.

  公开号：EP1807397A2

  公开（公告）日：2007-07-18
• US7662809B2
  申请人：——

  公开号：US7662809B2

  公开（公告）日：2010-02-16
• [EN] TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS<br/>[FR] DERIVES D'INDOLE TETRACYCLIQUES UTILISES COMME AGENTS ANTIVIRAUX
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2006046039A2

  公开（公告）日：2006-05-04

  [EN] The present invention relates to tetracyclic indole compounds of formula (I); wherein R¹, R², R¹⁴, R¹⁵, A, Ar, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.
  [FR] La présente invention concerne des composés d'indole tétracycliques de formule (I) dans laquelle R¹, R², R¹⁴, R¹⁵, A, Ar, Y et Z sont tels que définis, des sels de ceux-ci, acceptables d'un point de vue pharmaceutique, ainsi que des compositions pharmaceutiques comprenant lesdits composés et leur utilisation pour traiter ou prévenir une infection par le virus de l'hépatite C.